

REMARKS

By this Response, Claim 7 is amended. Support for the amended claim can be found in the original claim and in the Specification, for example, in page 4, lines 8-19. No new matter is entered.


In the Office Action dated February 9, 2006, the Examiner has set forth a requirement for restriction under 35 U. S. C. § 121. The Examiner contends that the subject matter defined by the claims of the present inventions is distinct and has acquired a separate status in the art.

In order to be fully responsive to the Examiner's requirement for restriction, Applicants provisionally elect to prosecute the subject matter of Group II, Claims 7-13 with amendment to Claim 7. Claim 7 is amended above to depend from Claim 1, the independent claim of Group I. Thus, the groups I and II are properly examined together.

In view of the foregoing comments, it is respectively urged that the Examiner reconsider both Group I, Claims 1-6, and Group II, Claims 7-13.

The Commissioner is authorized to charge any fees or credit any overpayment necessitated by this response to Deposit Account No. 18-1982.

Respectfully submitted,



Xuhong Sunny Wang, Reg. No. 54,524  
Patent Agent for Applicant

sanofi-aventis Inc. LLC  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807  
Telephone (908) 231-3648  
Telefax (908) 231-2626

Docket No. USAV2001/0172 US NP